Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,648,088
  • Shares Outstanding, K 61,457
  • Annual Sales, $ 77,430 K
  • Annual Income, $ -184,680 K
  • EBIT $ -266 M
  • EBITDA $ -250 M
  • 60-Month Beta 2.09
  • Price/Sales 47.60
  • Price/Cash Flow N/A
  • Price/Book 326.90

Options Overview Details

View History
  • Implied Volatility 41.61% ( +2.24%)
  • Historical Volatility 59.02%
  • IV Percentile 1%
  • IV Rank 5.20%
  • IV High 82.47% on 08/05/24
  • IV Low 39.36% on 11/19/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 100
  • Volume Avg (30-Day) 720
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 6,198
  • Open Int (30-Day) 9,020

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 10
  • High Estimate -0.41
  • Low Estimate -1.03
  • Prior Year -0.70
  • Growth Rate Est. (year over year) -5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.61 +24.68%
on 10/31/24
68.58 -13.44%
on 11/11/24
+8.51 (+16.74%)
since 10/18/24
3-Month
43.57 +36.24%
on 08/22/24
68.58 -13.44%
on 11/11/24
+13.75 (+30.15%)
since 08/20/24
52-Week
31.52 +88.30%
on 11/28/23
68.58 -13.44%
on 11/11/24
+26.02 (+78.04%)
since 11/20/23

Most Recent Stories

More News
Rhythm Pharmaceuticals Announces Positive Weight Reduction Results in Pediatric Patients Treated with Setmelanotide in Early-Access Program and Plans New Substudy for Congenital Hypothalamic Obesity

Four pediatric patients using setmelanotide therapy showed significant weight loss in a French early-access program, prompting further study.Quiver AI SummaryRhythm Pharmaceuticals announced promising...

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Publishes Positive Phase 3 VENTURE Trial Results for Setmelanotide in Young Children with Rare Genetic Obesity Conditions

Rhythm Pharmaceuticals reports Phase 3 trial results showing setmelanotide reduces hunger and weight in young children with severe obesity.Quiver AI SummaryRhythm Pharmaceuticals announced positive results...

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Announces New Employment Inducement Grants

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

RYTM : 59.36 (-1.02%)
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

RYTM : 59.36 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 63.49
2nd Resistance Point 62.14
1st Resistance Point 60.75
Last Price 59.36
1st Support Level 58.01
2nd Support Level 56.66
3rd Support Level 55.27

See More

52-Week High 68.58
Last Price 59.36
Fibonacci 61.8% 54.42
Fibonacci 50% 50.05
Fibonacci 38.2% 45.68
52-Week Low 31.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar